Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch
GeekWire
JULY 7, 2021
The company, a spin-out from the UW’s Institute for Protein Design , is developing vaccines to resemble naturally occurring viruses. Icosavax is also developing shots, geared for older adults, against two viruses that cause pneumonia, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Net losses were $5.3
Let's personalize your content